Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Long Focus Capital Management John B. Helmers | 2,741,853 | $4,140,198 | 0.12% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,281,501 | $4,955,067 | 3.06% | |
| 2. | 2,598,359 | $3,923,522 | 0% | |
| 3. | 246,414 | $372,085 | 0% | |
| 4. | 226,875 | $342,581 | 0% | |
| 5. | 86,366 | $130,413 | 0% |